

Ajer Jeffrey Robert  
 Form 4  
 September 26, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Ajer Jeffrey Robert

2. Issuer Name and Ticker or Trading Symbol  
 BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 EVP, Chief Commercial Officer

(Last) (First) (Middle)  
 C/O BIOMARIN  
 PHARMACEUTICAL INC., 105  
 DIGITAL DRIVE  
 (Street)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/22/2017

NOVATO, CA 94949  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock	09/22/2017 <sup>(1)</sup>	09/22/2017	M		1,355 A \$ 37.46	49,299	D
Common Stock	09/22/2017 <sup>(1)</sup>	09/22/2017	S		1,355 D \$ 95 <sup>(2)</sup>	47,944	D
Common Stock	09/22/2017 <sup>(1)</sup>	09/22/2017	M		2,166 A \$ 37.46	50,110	D
Common Stock	09/22/2017 <sup>(1)</sup>	09/22/2017	S		2,166 D \$ 95 <sup>(2)</sup>	47,944	D

Edgar Filing: Ajer Jeffrey Robert - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	
Stock Option (Right to buy Common Stock)	\$ 37.46	09/22/2017 <sup>(1)</sup>	09/22/2017	M	1,355	11/08/2012	05/07/2022	Common Stock	1,355
Stock Option (Right to buy Common Stock)	\$ 37.46	09/22/2017 <sup>(1)</sup>	09/22/2017	M	2,166	11/08/2012	05/07/2022	Common Stock	2,166

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

Ajer Jeffrey Robert  
C/O BIOMARIN PHARMACEUTICAL INC.,  
105 DIGITAL DRIVE  
NOVATO, CA 94949

EVP, Chief Commercial Officer

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

09/26/2017

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Trade made pursuant to a 10b5-1 plan executed on September 6, 2017.

(2) All shares were sold at the same price.

(3) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.